On October 6, 2020 OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intratumoral cancer immunotherapies, reported the issuance of a new patent covering its interleukin-12 (IL-12) based immunotherapy platform, including its lead product candidate TAVO (Press release, OncoSec Medical, OCT 6, 2020, View Source [SID1234568145]). Specifically, on October 6, 2020, the United States Patent and Trademark Office issued U.S. Patent No. 10,792,375, entitled Method for the Treatment of Malignancies, which covers the Company’s interleukin-12 (IL-12) based immunotherapy platform, including its lead product candidate TAVO, and its proprietary EP gene delivery system . This patent covers the use of intratumoral electroporation of DNA encoding interleukins (such as IL-12) to treat cancer and is significant because it is not specific to which type of immune-stimulatory interleukin can be used to treat a patient, nor is it limited to a particular type of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This new patent further strengthens our core intellectual property estate, broadening the exclusivity of OncoSec’s novel combination drug-device platform for the intratumoral delivery of immune-stimulatory interleukins," said Keir Loiacono, General Counsel and Vice President, Corporate Development at OncoSec. "The new IP serves to secure our competitive position in the intratumoral oncology space and builds on our patent portfolio of growing scope."

On October 6, 2020 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, reported that it will be presenting at the Alliance for Regenerative Medicine’s (ARM) virtual Cell and Gene Meeting on the Mesa, taking place October 12-16, 2020 (Press release, Genprex, OCT 6, 2020, View Source [SID1234568142]). Michael Redman, Executive Vice President and Chief Operating Officer of Genprex, will lead the company’s presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 2020 Cell and Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days where attendees will be able to watch company presentations on-demand, in addition to two live-streaming panels each day. The Cell and Gene Meeting on the Mesa is the sector’s foremost annual conference, bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies.

On October 6, 2020 AbbVie (NYSE: ABBV)reported that it will announce its third-quarter 2020 financial results on Friday, October 30, 2020, before the market opens (Press release, AbbVie, OCT 6, 2020, View Source [SID1234568139]). AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 6, 2020 Elthera reported that it has been awarded a non-dilutive grant from the Swiss Innovation Agency (Innosuisse) with a total budget of more than CHF 1.0 M. In collaboration with the Institute of Oncology Research (IOR) in Bellinzona (Switzerland), Elthera will use the grant to validate the target L1CAM in rare types of cancer (Press release, Elthera, OCT 6, 2020, View Source;utm_medium=rss&utm_campaign=elthera-and-the-institute-of-oncology-research-in-bellinzona-receive-innosuisse-grant [SID1234568135]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Gunther Spohn, CSO of Elthera, commented: "We are excited to initiate this collaboration with IOR, one of the most renowned cancer research organizations in Switzerland. The Innosuisse funds will allow us to explore the therapeutic potential of our anti-L1CAM compounds in rare types of cancer, which are not adequately treated with current therapies. By combining Elthera’s knowledge in the development of therapeutic antibodies and IOR’s expertise in basic and translational research in rare cancer types we aim to develop new efficacious immunotherapies for diseases, which are often neglected by global drug development companies."

Prof. Francesco Bertoni, Deputy Director of IOR, commented: "The collaboration with Elthera will allow us to elucidate the role of L1CAM in the development and progression of rare malignancies, where a high medical need for better treatment exists. By elucidating L1CAM-dependent disease mechanisms and establishing the efficacy of Elthera’s anti-L1CAM compounds in preclinical disease models, we aim to lay the ground for new and better therapies for the affected patients."

On October 6, 2020 Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported that Halozyme and argenx are expanding their existing global collaboration and license agreement that was signed in February 2019 (Press release, Halozyme, OCT 6, 2020, View Source [SID1234568134]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the newly announced expansion, argenx gained the ability to exclusively access Halozyme’s ENHANZE drug delivery technology for three additional targets upon nomination for a total of up to six targets under the existing and newly expanded collaboration. To date, argenx has nominated two targets including the human neonatal Fc receptor FcRn and complement component C2.

"We are pleased to be expanding the scope of our collaboration with Halozyme and to continue our productive relationship. We recognize that patients have different preferences and we want to secure our ability to offer subcutaneous delivery of our current and future candidates to reach as many patients as possible. We already have exclusive access to ENHANZE for our FcRn antagonist efgartigimod, which is in late stage development for multiple severe autoimmune diseases, and additionally have nominated our complement inhibitor targeting C2," said Keith Woods, Chief Operating Officer of argenx.

"We are delighted that argenx has agreed to expand our global collaboration and license agreement to include up to six targets," said Dr. Helen Torley, president and chief executive officer. "argenx has made rapid progress in the clinic with efgartigimod utilizing ENHANZE since signing the original agreement, moving to a Phase 2 study initiation for an indication being developed only as SC, within just fourteen months. argenx is also working to bring SC efgartigimod to patients suffering from myasthenia gravis following the successful ADAPT trial results."